Non-hormonal therapy for climacteric syndrome: efficacy, safety and a clinical rationale
Lechaschi Vrach · 20.05.2026 · (5(29))
DOI: 10.51793/os.2026.29.5.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lechaschi Vrach, erschienen am 20.05.2026. Verfasst von E.D. Begovich und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Climacteric syndrome is characterised by a combination of neurovegetative, psycho-emotional, and metabolic disorders, secondary to estrogen deficiency during the perimenopausal transition and postmenopause. Epidemiological studies suggest that up to 80% of peri- and postmenopausal women experience climacteric symptoms, including hot flashes, night sweats, anxiety, depression, sleep disturbances, a decline in libido, and genitourinary syndrome of menopause. Despite the high efficacy of menopausal hormone therapy, its clinical use is limited by contraindications and patient concerns regarding safety. Consequently, there is growing interest in non-hormonal therapies, including phytoestrogens, amino acids, and micronutrients. The most extensively studied components of non-hormonal therapy include phytoestrogens, amino acids, antioxidants and vitamins, providing a more comprehensive intervention targeting the pathogenesis of climacteric disorders. Phytoestrogens (soy and red clover isoflavones) can selectively bind to estrogen receptors β, exerting mild estrogen-like activity and alleviating vasomotor symptoms. The amino acids β-alanine and tryptophan are involved in the modulation of neurotransmition, including the synthesis of serotonin and melatonin, which improves sleep quality, reduce anxiety and the frequency of hot flashes. Antioxidants, particularly resveratrol, possess anti-inflammatory and cardioprotective properties, thereby improving cognitive functions and mitigating the risk of metabolic dysfunction, common in postmenopausal women. Vitamins B, C and E are involved in neurotransmitter synthesis, provide antioxidant protection and maintain optimal functioning of the nervous and cardiovascular systems, which alleviates climacteric symptoms.
Objective
The present study aims to evaluate clinical data supporting the efficacy and safety of a dietary supplement, which contains red clover isoflavones, resveratrol, β-alanine, 5-hydroxytryptophan, and vitamins B, C and E for the treatment of menopausal symptoms.
Conclusion
The body of evidence indicates that non-hormonal complexes derived from phytoestrogens and micronutrients can alleviate vasomotor symptoms, enhance psycho-emotional well-being and improve the quality of life in female patients while maintaining a favorable safety profile.
Zitieren
APA
Begovich, E., & Gasparyan, S. (2026). Non-hormonal therapy for climacteric syndrome: efficacy, safety and a clinical rationale. Lechaschi Vrach. https://doi.org/10.51793/os.2026.29.5.017
Vancouver
Begovich E, Gasparyan S. Non-hormonal therapy for climacteric syndrome: efficacy, safety and a clinical rationale. Lechaschi Vrach. 2026. doi:10.51793/os.2026.29.5.017
BibTeX
@article{Begovich2026,
author = {Begovich, E.D. and Gasparyan, S.A.},
title = {Non-hormonal therapy for climacteric syndrome: efficacy, safety and a clinical rationale},
journal = {Lechaschi Vrach},
year = {2026},
number = {5(29)},
doi = {10.51793/os.2026.29.5.017}
}
EUVIMED